News from J&J, Teva and Amarantus – People on the move

By Natalie Morrison

- Last updated on GMT

Related tags Medicine

News from J&J, Teva and Amarantus – People on the move presents its weekly round-up of the latest new appoitnments within the world of pharma and biopharma including news from J&J, Teva and Amarantus.

Johnson & Johnson (J&J) ​has drafted Eugene Washington ​ onto its board of directors.

Washington – the vice chancellor for University of California and LA (UCLA) – also currently serves as chairman of the board for the Patient-Centered Outcomnes Research Institute.

"Gene has dedicated his life to improving health care as a practitioner, researcher, teacher, administrator, and policy advisor.  He brings our board valuable leadership and insight into analysing health care policy, assessing medical technologies, and sharing forward-looking perspectives on the role we can play in addressing the world's health care challenges,"​ said Bill Weldon, J&J chairman.

Teva Pharmaceuticals ​has named Jill DeSimone​ its new senior VP and general manager of Teva Global Women’s Health division.

Previously she worked for Bristol-Myers Squibb where she was senior VP of US commercialisation excellence.

Meanwhile Allan Oberman​, currently the firm’s senior VP of North America generic pharmaceuticals will take on the role of president and CEO of Teva Americas Generics. He replaces William Marth​, who will become a senior advisor until his retirement next year.

Jeremy Levin, president and CEO of the Teva group, said the changes were part of the decision to “reshape”​ the firm’s leadership team.

He said: “These changes underlie our commitment to build, in a disciplined fashion, a world class business and provide much needed medicines to patients around the world."

Oncos Therapeutics ​has appointed Frans Wuite ​its new president and CEO.

Frans Wuite – who also owns a management consulting for life science firm named Owner Kompassi – joins the firm from Cryo-Save Group where he was a management consultant.

Founding CEO Pekka Simula​ will now take on the role of chief operating officer.

Joseph Rubinfeld​ has joined the Amarantus BioSciences ​corporate advisory board.

Rubinfield, who co-founded Amgen, will work with management over development programs for partnering and business strategies for the firm’s proprietary anti-apoptosis therapeutic protein MANF.

He said: "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.

“I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."

Thom Rowland ​will become VP of commercial operations for Arbor Pharmaceuticals​.

Previously he was chief business officer at Ventrus Biosciences.

Ed Schutter, President and CEO of Arbor, said: "As our business grows and we become more complex, we felt it was essential that we have someone of Thom's level of experience on board.”

Related topics Markets & Regulations

Related news

Show more